Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on ...

Bank of America Securities analyst Tazeen Ahmad has reiterated their bearish stance on SAGE stock, giving a Sell rating on October 4. Tazeen ...

Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...

Fintel reports that on October 4, 2024, RBC Capital downgraded their outlook for Sage Therapeutics (NasdaqGM:SAGE) from ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.